跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 40 条关于
“SAR443579/IPH6101”
全部
40
临床试验
27
药物
3
机构
0
资讯
10
2年前
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579/IPH6101 to Phase 2 for Blood Cancer Patients
2年前
Innate Pharma Advances Oncology Pipeline with Lacutamab, ANKET, and ADC Programs
去年
NK Cell Therapy Pipeline Shows Promise with Over 160 Therapies in Development
3年前
Sanofi to Present New Oncology Data at ASCO 2023
5个月前
Innate Pharma Advances Oncology Pipeline with Phase 3 Trial Plans and Promising ADC Data
去年
Innate Pharma Advances Key Pipeline Assets While Implementing Strategic Restructuring
去年
Tetraspecific NK Cell Engager IPH6501 Shows Promise in B-NHL Treatment
去年
Innate Pharma and IFLI Partner to Advance IPH6501 in Follicular Lymphoma
去年
Innate Pharma's Novel NK Cell Engager IPH6501 to Be Presented at EHA 2025 Congress
去年
Sanofi's SAR446597 Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy Treatment